-
Posted by
Two Blokes Jul 3 -
Filed in
Stock
-
5 views
I've upgraded Teladoc to a tepid buy—not a full conviction call, but the numbers finally tilt in its favor. I believe the company's innovative platform positions it as a leader in digital healthcare, driving long-term value. 7x forward free cash flow is just too low to ignore, even with weak top-line growth.
